CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
补充β-羟基丁酸可增强 CAR-T 细胞的肿瘤杀伤潜力
英文原题：β-hydroxybutyrate supplementation boosts the tumor-killing potential of CAR T cells.
查看英文原题
β-hydroxybutyrate supplementation boosts the tumor-killing potential of CAR T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在最近发表于Cell的一项研究中，Liu等人发现β-羟基丁酸可作为CAR-T 细胞实用的代谢佐剂。通过为TCA循环提供燃料并重塑转录和表观遗传程序，这种酮体增强了增殖、持久性和肿瘤控制，提示代谢补充可能为更有效的过继免疫治疗提供一条简单途径。
展开英文摘要原文
In a recent study in Cell, Liu et al. identify β-hydroxybutyrate as a practical metabolic adjuvant for CAR-T cells. By fueling the TCA cycle and reshaping transcriptional and epigenetic programs, this ketone body enhances proliferation, persistence, and tumor control, suggesting that metabolic supplementation may offer a simple route to more effective adoptive immunotherapy.
论文信息
- 作者
- Adamopoulos C、Papavassiliou KA、Papavassiliou AG
- 第一作者单位
- Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.Greece
- 通讯作者单位
- Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: papavas@med.uoa.gr.Greece
- 期刊
- Trends in molecular medicine2026 Jul
- 原文标识
- PubMed 41986177 · DOI 10.1016/j.molmed.2026.04.001